Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264179 | 0.78 | GPR119 (0.54) | MAPTSMN1; SMN2GPR119HTT | |
| SCHEMBL27652159 | 0.77 | GPR119 (0.64) | MAPTSMN1; SMN2GPR119NPC1HTT | |
| SCHEMBL1673899 | 0.77 | GPR119 (0.48) | MAPTSMN1; SMN2GPR119HSPB1TRPA1 | |
| SCHEMBL1673883 | 0.76 | GPR119 (0.49) | MAPTSMN1; SMN2GPR119HSPB1TRPA1 | |
| SCHEMBL1673604 | 0.75 | GPR119 (0.69) | MAPTGPR119NPC1 | |
| SCHEMBL27631974 | 0.71 | GPR119 (0.61) | GPR119 | |
| SCHEMBL5262369 | 0.71 | GPR119 (0.60) | MAPTSMN1; SMN2GPR119 | |
| SCHEMBL5264849 | 0.71 | GPR119 (0.52) | MAPTSMN1; SMN2GPR119 | |
| SCHEMBL1673743 | 0.70 | GPR119 (0.59) | MAPTGPR119 | |
| SCHEMBL390087 | 0.69 | GPR119 (0.50) | MAPTSMN1; SMN2GPR119HSPB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293751-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | UGT1A1, GPR119, UGT1A3 | MAPT 4467/4885SMN1; SMN2 4827/4885GPR119 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.